AMG 820

Drug Profile

AMG 820

Alternative Names: AMG-820

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Amgen
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 10 May 2016 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in Canada (IV) (NCT02713529)
  • 10 May 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) in USA (IV) (NCT02713529)
  • 16 Apr 2016 Efficacy and safety data from a phase I trial in Solid tumours presented at the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top